Protocol: Filgotinib in addition to methotrexate versus filgotinib monotherapy in patients with rheumatoid arthritis with an inadequate response to methotrexate: A multicenter, prospective, open-label, randomized controlled trial (FAITHFUL Study).
<h4>Background</h4>Filgotinib (FIL), a Janus kinase-1 preferential inhibitor, has been studied for its efficacy and safety in rheumatoid arthritis. The FINCH3 trial compared FIL monotherapy, FIL plus methotrexate (MTX) combination therapy, and MTX monotherapy in MTX-naïve patients. Howev...
Saved in:
| Main Authors: | Mitsuhiro Akiyama, Toshihiko Hidaka, Motohide Kaneko, Satoshi Ito, Hiroaki Taguchi, Tomonori Ishii, Shuji Asai, Shintaro Hirata, Kei Ikeda, Katsuya Suzuki, Naoki Kato, Yuko Kaneko |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2025-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0322621 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Filgotinib Radiographic and Clinical Efficacy Versus Other JAK Inhibitors and Adalimumab in Patients With Rheumatoid Arthritis and Inadequate Response to Methotrexate: A Systematic Review and Network Meta-Analysis
by: Yoshiya Tanaka, et al.
Published: (2025-04-01) -
In which patients with ulcerative colitis would filgotinib be effective?
by: Jihye Park
Published: (2025-01-01) -
Impact of filgotinib on pain control in the phase 3 FINCH studies
by: Bruno Fautrel, et al.
Published: (2024-02-01) -
Efficacy and safety of sarilumab in combination with methotrexate in patients with active rheumatoid arthritis and inadequate effect of methotrexate monotherapy (results of phase III MOBILITY study)
by: E. L. Nasonov, et al.
Published: (2019-05-01) -
Upadacitinib as monotherapy in patients with rheumatoid arthritis and prior inadequate response to methotrexate: results at 260 weeks from the SELECT-MONOTHERAPY randomised study
by: Josef S Smolen, et al.
Published: (2025-05-01)